COVID-19 Clinical Features and Outcome in Italian Patients Treated with Biological Drugs Targeting Type 2 Inflammation

Life, Год журнала: 2024, Номер 14(3), С. 378 - 378

Опубликована: Март 13, 2024

This is a multicentric investigation involving two Italian centers that examined the clinical course of COVID-19 in patients receiving biological therapy targeting type 2 inflammation and those not biologicals. Since beginning pandemic, management respiratory allergic disorders potential impact most severe forms has been point uncertainty. Our aimed to compare vaccination an cohort with atopic caused by inflammation, such as eosinophilic asthma, chronic rhinosinusitis nasal polyposis (CRSwNP), dermatitis (AD), spontaneous urticaria (CSU). A questionnaire was given coming our outpatient clinic for first evaluation or follow-up visit, asking characteristics infection, ongoing during any relevant change, patient’s status. We enrolled 132 from centers; 62 were on at time infection (omalizumab 31%, mepolizumab 26%, benralizumab 19%, dupilumab 24%). The median age 56 (IQR 22.8) biologicals 48 26.5) (p = 0.028). groups comparable terms sex, body mass index (BMI), smoking history, systemic oral corticosteroid use (OCS). There no significant differences non-biological comorbidity between groups. had prevalence 87% 52% CRSwNP, 10% CSU, 6% AD. 93% 17% CSU. In work, we observed mAbs appeared be safe, worsening symptoms, prolongation increase hospitalizations. Between groups, there duration swab positivity 0.45) symptoms 0.38). During COVID-19, experienced common cold-like 0.038), dyspnea 0.016), more, but significant, asthma exacerbations, different Regarding status, increased number hospitalizations among unvaccinated both although difference did reach statistical significance. No reported safety issues adverse effects associated treatments COVID-19. showed against Coronavirus Disease 2019 are safe do main outcomes. Therefore, found signals suggesting anti-Th2 should discontinued SARS-CoV-2 infection. Controlled studies analysis, including data registries real-life studies, required draw firm conclusions regarding possible advantages anti-type could offer particular contexts, infections.

Язык: Английский

Effect of omalizumab on inflammatory markers in COVID-19: an exploratory analysis of the COVID-19 immunologic antiviral therapy with omalizumab (CIAO) trial

Frontiers in Medicine, Год журнала: 2024, Номер 11

Опубликована: Ноя. 19, 2024

The CIAO trial recently demonstrated a probable clinical benefit of omalizumab in the treatment severe COVID-19; however, mechanism underlying this remains unclear. Therefore, we sought to longitudinally assess impact on serum cytokines patients determine its action.

Язык: Английский